General
Preferred name
BENDAMUSTINE
Synonyms
BENDAMUSTINE HYDROCHLORIDE ()
Bendamustine D4 ()
EP-3101 ()
SDX-105 D4 ()
SDX-105 ()
SDX-105 (Cytostasane) HCl ()
Bendamustine HCl ()
SDX105 ()
Bendamustine (hydrochloride) ()
SDX-105 (free base) ()
Cytostasane HCl ()
Bendamustine (SDX105) HCl ()
Bendamustine (SDX105) ()
bendamustine hydrochlorideRibomustinTreandaIMET 3393Cytostasan2-Benzimidazolinebutryric acid, 1-methyl-5-bis(2-chloroethyl)amino-, hydrochlorideSDX-105WLN: T56 BN DNJ B1 C3VQ GN2G2G &GH1H-Benzimidazole-2-butanoic acid, 5-[bis(2-chloroethyl)amino]-1-methyl-, monohydrochloride2-Benzimidazolebutyric acid, 5-[bis(2-chloroethyl)amino]-1-methyl-, monohydrochloride ()
NSC-138783 ()
Ribomustine ()
Treanda ()
Belrapzo ()
SYBL-0501 ()
SYB L-0501 ()
Ribomustin ()
Bendeka ()
Vivimusta ()
Bendamustina ()
Bendamustine-d4 (hydrochloride) ()
P&D ID
PD003516
CAS
16506-27-7
3543-75-7
2802569-31-7
Tags
available
drug
Approved by
PMDA
FDA
First approval
2008
Drug indication
leukaemia
Chronic lymphocytic leukemia
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
TOXICITY Risk for tumor-lysis syndrome.; Discontinue use in the event of severe/progressive skin reactions. ; Hematologic malignancies of different forms reported.; Discontinue use in the case of severe infusion reactions. ; May cause extravasation.; Mild to moderate renal impairment.; Mild hepatic impairment. ; Sepsis (infections) may occur.; Avoid use if pregnant. ; Possibility of anaphylaxis or infusion reactions- severe in rare cases.
DESCRIPTION The marketed formulation contains the hydrochloride salt (PubChem CID 77082). (GtoPdb)
DESCRIPTION Bendamustine (SDX-105 free base), a purine analogue, is a DNA cross-linking agent. Bendamustine activates DNA-damage stress response and apoptosis. Bendamustine has potent alkylating, anticancer and antimetabolite properties[1].
PRICE 93
PRICE 29
DESCRIPTION Bendamustine hydrochloride (SDX-105), a purine analogue, is a DNA cross-linking agent. Bendamustine hydrochloride activats DNA-damage stress response and apoptosis. Bendamustine hydrochloride has potent alkylating, anticancer and antimetabolite properties[1].
DESCRIPTION Bendamustine hydrochloride (EP-3101) (IC50 of 50 ??M) is an alkylating agent associated with DNA damage.
DESCRIPTION DNA alkylator (Informer Set)
DESCRIPTION Bendamustine, a lbenzimidazol derivative, has been found to be an alkylating agent that acts through restraining DNA synthesis so that could be useful as an antineoplastic agent. (BOC Sciences Bioactive Compounds)
DESCRIPTION Bendamustine (SDX105) for the treatment of Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia (TargetMol Bioactive Compound Library)
DESCRIPTION Restores mutant p53 activity (Tocris Bioactive Compound Library)
DESCRIPTION Bendamustine is an antineoplastic agent used for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma that has progressed following rituximab therapy. Bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. (Enamine Bioactive Compounds)
DESCRIPTION Bendamustine hydrochloride (EP-3101) (IC50 of 50 μM) is an alkylating agent associated with DNA damage. (TargetMol Bioactive Compound Library)
Cell lines
5
Organisms
0
Compound Sets
28
AdooQ Bioactive Compound Library
A10124
BOC Sciences Bioactive Compounds
bendamustine-cas-16506-27-7-item-60437
Cayman Chemical Bioactives
23693
31316
ChEMBL Approved Drugs
CHEMBL487253
CHEMBL1201734
ChEMBL Drugs
CHEMBL487253
CHEMBL1201734
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB06769
DrugBank Approved Drugs
DB06769
DrugCentral
302
DrugCentral Approved Drugs
302
DrugMAP
DMFH15Z
DrugMAP Approved Drugs
DMFH15Z
Enamine Bioactive Compounds
EBC-17087
EU-OPENSCREEN Bioactive Compound Library
EOS102463
Guide to Pharmacology
7478
Informer Set
374755
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL487253
MedChem Express Bioactive Compound Library
HY-13567
HY-B0077
NCATS Inxight Approved Drugs
9266D9P3PQ
NIH Approved Oncology Drugs
558674
NPC Screening Collection
Other bioactive compounds
ReFrame library
Selleckchem Bioactive Compound Library
bendamustine
Bendamustine-Hydrochloride
TargetMol Bioactive Compound Library
T8380
T0095
The Spectrum Collection
Tocris Bioactive Compound Library
3681
External IDs
66
Properties
(calculated by RDKit )
Molecular Weight
357.1
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
9
Ring Count
2
Aromatic Ring Count
2
cLogP
3.26
TPSA
58.36
Fraction CSP3
0.5
Chiral centers
0.0
Largest ring
6.0
QED
0.7
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Compound status
FDA
Target
DNA alkylator/crosslinker
Apoptosis
DNA synthesis
DNA/RNA Synthesis
Pathway
Cell Cycle/DNA Damage
Cell Cycle/Checkpoint
DNA Damage/DNA Repair
Primary Target
Apoptosis Inducers
Indication
chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL)
MOA
DNA inhibitor
Source data